Can This Drug “Do That”? The Internet Keeps Asking. Pharmacology Keeps Sighing.
If you’ve spent any time in healthcare—whether as a clinician, investor, founder, or patient—you’ve seen the same pattern play out online: someone asks whether a drug can t…

Stop the DIY Patent Search: The FTO Opinion That Could Save You From “Willful” Infringement
In pharma, the most expensive mistake is often the one you don’t realize you made—because you thought you were being careful.
A growing number of companies are …

Stop the DIY Patent Search: The FTO Opinion That Could Save You From “Willful” Infringement
In pharma, the most expensive mistake is often the one you don’t realize you made—because you thought you were being careful.
A growing number of companies are …

Pharma doesn’t always “win” new patents. Sometimes it wins time.
Drug Patent Watch’s latest piece on patent term extensions (PTEs) is a reminder that the real battleground in Big Pharma isn’t just discovery—it’s duration. In a sector where a single yea…

Generic drugmakers don’t just “wait for patents to expire.” They litigate their way to the starting line.
That’s the core lesson from The Hatch Waxman Playbook: How Generic Drugmakers Use Patent Litigation to Get to Market Early—a reminder that the U…

Drugmakers don’t lose contracts because they miss demand—they lose because they miss timing.
As patent cliffs approach, the industry’s most valuable asset isn’t just a reformulated molecule. It’s a package—the ability to show payers, pharmacy benefit…

Old Drugs, New Signals: What the Side-Effect Conversation Is Really Saying
The side-effect conversation is getting louder—and it’s not just about safety.
Over the past few years, the industry has shifted from a simple question—“Does this drug work?”—to…

Drug patents aren’t “assets”—they’re risk engines. Here’s why acquisition values are getting rewritten by litigation costs.
In deal rooms, drug patents are often treated like clean, durable assets: a defined term, a defined scope, a defined path to exc…

Most NDAs Don’t Fail on Science. They Fail on Strategy.
In pharma, we love to talk about molecules—mechanisms, trial design, endpoints, and the elegance of the data. But anyone who’s shepherded an NDA knows the uncomfortable truth: the submission is …